Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand · Injection · Updated Nov 11, 2026

Retacrit 20000 units/mL injection price what pharmacies pay, and what you should

Pharmacies pay$2,247.88for 10 mL · $224.79 per mL
Fair cash price$2,595.56cost + 15% + $10.50 fee
No change in 4 weeks+5.2% in a yearLast change Jul 1, 2026: WAC Adjustment

Is my price fair?

Check the price you were quoted

Type what the pharmacy asked for retacrit 20000 units/ml injection and see the markup over what they pay.

How many?
$
Pharmacies payNADAC this week$2,247.88
Online cost-pluscost + 15% + fees$2,595.06
Fair cash pricecost + 15% + $10.50 fee$2,595.56
Your quotetype it above-
Pharmacies pay about $2,247.88 for 10 mL. A fair cash price is around $2,595.56. Type your quote to see your markup.

A benchmark from public data, not a price offer or medical advice. Prices vary by pharmacy, insurance and discount programs.

Retacrit 20000 units/mL price history

What pharmacies pay for 10 mL, weekly
$2,122.39$2,169.36$2,216.32$2,263.29DecFebAprJunAugOct
What pharmacies paid for 10 mL of retacrit 20000 units/ml injection over 52 weeks: from $2,137.80 on Nov 12, 2025 to $2,247.88 on Nov 11, 2026.
Now
$2,247.88
52-week low
$2,137.80
52-week high
$2,247.88
A year ago
$2,137.80

Why the price changed

EffectiveBeforeAfterChangeReason
Jul 1, 2026$219.39$224.79+2.5%WAC Adjustment
Jan 1, 2026$214.12$219.39+2.5%WAC Adjustment
Dec 17, 2025$213.78$214.12+0.2%pharmacies' invoice prices changed (survey)

Prices per mL. Reasons are the ones the national survey gives: a survey rate change comes from pharmacies' own invoices; a published price change follows the maker's list price.

What did you pay for retacrit 20000 units/ml injection? Share it.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Supply status: shortages & recalls

No shortage reportedChecked Nov 18, 2026
No ongoing recalls1 recall on record

Recalls

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

Every manufacturer and package code

1 company sell retacrit 20000 units/ml injection under 1 package code (NDC).

MakerPack sizesPackage codesPer unit
Pfizer Laboratories Div Pfizer Inc100069-1311-10 $224.79
All 1 package codes

A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.

Questions to ask your pharmacist

  1. "What is your cash price, without insurance?" For low-cost generics it can be less than a copay.
  2. "Would 2000 units/mL, 1 mL injection work for me instead?" Pharmacies pay $22.52 per mL for it, against $224.79 for this one. Only your prescriber can say whether a different strength or form suits you.
  3. "Do you match other pharmacies or accept discount cards?" Many do, if you ask.

These are questions, not advice. Never change how you take a medicine without talking to your prescriber or pharmacist.

Other retacrit strengths and forms

Strength and formPer unitPharmacies pay4 weeks52 weeks
2000 units/mL, 1 mL injection Brand$22.52$225.23 / 10 mLNo change+5.2%
10000 units/mL, 1 mL injection Brand$112.68$1,126.83 / 10 mLNo change+5.0%
40000 units/mL, 1 mL injection Brand$448.01$1,792.03 / 4 mLNo change

Official label & what changed

Last changedJune 26, 2025
Version19 of 13
EffectiveJun 22, 2025
Read the label

These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT® (epoetin alfa-epbx) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2018 RETACRIT (epoetin alfa-epbx) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clini

This drug has a boxed warning

WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE

WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE

See full prescribing information for complete boxed warning.

Chronic Kidney Disease:

•

In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL (5.1).

•

No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks (2.2).

•

Use the lowest RETACRIT dose sufficient to reduce the need for red blood cell (RBC) transfusions (5.1).

Cancer:

•

ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (5.2).

•

Use the lowest dose to avoid RBC transfusions (2.4).

•

Use ESAs only for anemia from myelosuppressive chemotherapy (1.3).

•

ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure (1.5).

•

Discontinue following the completion of a chemotherapy course (2.4).

Perisurgery:

•

Due to increased risk of deep venous thrombosis (DVT), DVT prophylaxis is recommended (5.1).

Chronic Kidney Disease:

•

In controlled trials, patients with chronic kidney disease (CKD) experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL [see Warnings and Precautions (5.1)].

•

No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks [see Dosage and Administration (2.2)].

•

Use the lowest RETACRIT dose sufficient to reduce the need for red blood cell (RBC) transfusions [see Warnings and Precautions (5.1)].

Cancer:

•

ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers [see Warnings and Precautions (5.2)].

•

To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusions [see Dosage and Administration (2.4)].

•

Use ESAs only for anemia from myelosuppressive chemotherapy [see Indications and Usage (1.3)].

•

ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure [see Indications and Usage (1.5)].

•

Discontinue following the completion of a chemotherapy course [see Dosage and Administration (2.4)].

Perisurgery:

•

Due to increased risk of deep venous thrombosis (DVT), DVT prophylaxis is recommended [see Dosage and Administration (2.5), Warnings and Precautions (5.1)].

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Questions about retacrit 20000 units/ml injection

How much does retacrit 20000 units/ml injection cost without insurance?

Pharmacies pay about $2,247.88 for 10 mL ($224.79 per mL) as of November 11, 2026. A fair cash price is about $2,595.56: that cost plus a 15% margin and a $10.50 dispensing fee. Online cost-plus pharmacies charge around $2,595.06 including shipping.

Is my price for retacrit 20000 units/ml injection fair?

Compare it with the fair cash price of $2,595.56 for 10 mL. Up to about $3,244.45 is fair; above $5,191.12 is high, and worth asking the pharmacy for its cash price or trying another pharmacy. Check your quote.

Is retacrit 20000 units/ml injection getting more expensive?

Over the last four weeks the price pharmacies pay held steady. Over a year it rose 5.2%. See the 52-week chart.

Who makes retacrit 20000 units/ml injection?

1 company: Pfizer Laboratories Div Pfizer Inc. See every package code.

Is retacrit in shortage?

No shortage is reported right now. We check every day.

Has retacrit been recalled?

1 recall on record. Recalls name specific lots - check yours.

What does "pharmacies pay" mean?

It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.

Talk about retacrit 20000 units/ml injection

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.